Corporate ActionJul 23, 2026, 08:47 AM
China SXT Pharmaceuticals to Raise $9M via Direct Offering
AI Summary
China SXT Pharmaceuticals, Inc. announced a definitive securities purchase agreement with institutional investors for a registered direct offering. The company will sell 4,500,000 units, each comprising one Class A ordinary share and one common warrant, at $2.00 per unit. This offering is expected to generate approximately $9 million in gross proceeds. The warrants will be immediately exercisable at $3.20 per share and expire one year from issuance. The transaction is anticipated to close around July 24, 2025.
Key Highlights
- Entered securities purchase agreement with institutional investors.
- Offering 4,500,000 units in a registered direct offering.
- Each unit includes one Class A ordinary share and one common warrant.
- Purchase price set at $2.00 per unit.
- Warrants exercisable at $3.20 per share, expiring in one year.
- Expected gross proceeds of approximately $9 million.
- Closing anticipated around July 24, 2025.
- Univest Securities, LLC is the sole placement agent.
Price Impact
More from SXTC